Examining the TRIPs Agreement: Impact on Global Intellectual Property Rights

When 164 countries agree to a single set of rules governing who owns an idea, a drug formula, or a seed variety, the consequences reach far beyond trade statistics. The Agreement on Trade-Related Aspects of Intellectual Property Rights – universally known as TRIPs – is exactly that kind of agreement. Administered by the World Trade Organization (WTO), it has shaped global intellectual property law since coming into force in 1995, and it remains one of the most debated agreements in the history of international trade. The core controversy is straightforward: TRIPs was designed to protect innovators, but critics argue it has done so in ways that disadvantage developing countries, restrict access to life-saving medicines, allow the appropriation of indigenous knowledge, and skew the balance of global economic power.

What TRIPs actually does 🔗

TRIPs was negotiated at the end of the Uruguay Round of trade talks between 1989 and 1990, and it represented something genuinely new: for the first time, intellectual property law was brought into the multilateral trading system. Before TRIPs, countries could set their own rules on patents, copyrights, and trademarks. After TRIPs, all WTO members were bound to a common floor of minimum standards.

The agreement covers a wide range of intellectual property categories – copyrights, patents, trademarks, geographical indications, industrial designs, and trade secrets. Its basic principles are national treatment and most-favoured-nation treatment, meaning WTO members must treat the IP rights of foreign nationals no less favourably than those of their own citizens. On patents specifically, TRIPs requires that all inventions be eligible for patent protection for a minimum of 20 years, regardless of the field of technology involved.

Crucially, TRIPs is not merely an aspirational framework – it has a powerful enforcement mechanism through the WTO’s dispute settlement system, which can authorise trade sanctions against non-compliant countries. This is precisely what gave TRIPs its teeth, and what makes it qualitatively different from earlier international IP conventions.

Transition periods for developing countries 🔗

Recognising that not all WTO members start from the same position, TRIPs built in differentiated timelines for compliance. Developed countries were required to fully implement the agreement by January 1996, while developing countries were given until January 2000, and least-developed countries until January 2006 – with further extensions available upon request. In practice, these deadlines have been extended multiple times, particularly for pharmaceutical patents in least-developed countries. The rationale was to give poorer nations time to build the legal infrastructure needed to comply. In reality, as we’ll see, the time extensions only delayed a set of deeper structural challenges.

The medicines crisis: where TRIPs became most controversial 🔗

No aspect of TRIPs generated more international outcry than its impact on access to medicines. The agreement’s patent protections – especially for pharmaceuticals – meant that multinational drug companies could maintain exclusive rights over life-saving treatments, keeping prices high and generic alternatives off the market.

Developing countries make up approximately 80% of the world’s population but account for only around 20% of global pharmaceutical consumption. This disparity is driven by many factors, but TRIPs-enforced patent monopolies are a significant contributor. By limiting competition and local manufacturing, TRIPs risked extending high drug prices and worsening the access-to-medicines crisis, treating life-saving treatments as ordinary consumer goods while the devastating impact of unaffordable prices went largely unaddressed.

The HIV/AIDS epidemic in sub-Saharan Africa brought this tension to a head. Antiretroviral drugs existed but were priced far beyond what affected populations – or their governments – could afford. The price of maintaining patent monopolies was being measured in human lives.

The Doha Declaration: a turning point 🔗

A longstanding debate over the relationship between intellectual property and public health intensified in the lead-up to the WTO’s 2001 Ministerial Conference in Doha, partly driven by concerns over new treatments for HIV/AIDS. The result was the Doha Declaration on the TRIPS Agreement and Public Health, adopted in November 2001.

The Declaration confirmed that the TRIPs Agreement does not and should not prevent members from taking measures to protect public health, and reaffirmed the right of WTO members to use the agreement’s built-in flexibilities – including compulsory licensing – to promote access to medicines for all. Compulsory licensing allows governments to authorise the manufacture or import of a patented medicine without the patent holder’s consent, particularly in public health emergencies.

However, a practical problem remained. The original TRIPs rules required that any compulsory licence be issued mainly to serve the domestic market, which created a serious barrier for countries with no pharmaceutical manufacturing capacity of their own. They could not produce the generic drugs themselves and faced legal obstacles to importing them. To resolve this, WTO members agreed in 2005 to legally amend TRIPs, creating a new compulsory licence mechanism specifically designed for the export of medicines to countries in need – an amendment that entered into force in 2017.

Despite these developments, the Doha framework has not fully resolved the problem. Many developing countries have come under pressure to enact even tougher patent conditions than TRIPs requires – known as “TRIPs-plus” provisions – as part of bilateral trade agreements with the United States or the European Union, with damaging consequences for medicine access.

Agriculture, seeds, and farmer rights 🔗

The impact of TRIPs on agriculture is less widely discussed but equally significant. The agreement requires WTO members to provide patent protection or an equivalent system for plant varieties, opening the door to the intellectual property-isation of seeds and agricultural biotechnology.

For farming communities in developing countries, this has serious practical consequences. When large agribusinesses patent seed varieties or agricultural processes, small-scale farmers who have long relied on saving, exchanging, and replanting seeds can find themselves legally constrained or financially dependent on corporate suppliers. In countries where agriculture is the primary economic activity, this dynamic can deepen rural poverty and erode food sovereignty.

Article 27.3(b) of TRIPs, which deals with the patentability of plant and animal inventions, has been a particular point of contention, with the 2001 Doha Declaration calling for an expanded review of this provision that would also consider its relationship to the UN Convention on Biological Diversity (CBD) and the protection of traditional knowledge. Critics argue the current text of Article 27.3(b) was shaped by a compromise between Europe and the United States, with little genuine consideration of the interests of developing countries, farming communities, or the principles embedded in the CBD.

Indigenous knowledge and the biopiracy problem 🔗

Perhaps the most ethically charged critique of TRIPs concerns its relationship to indigenous knowledge. Communities across Asia, Africa, and Latin America have developed rich bodies of knowledge over generations – about medicinal plants, agricultural techniques, ecological systems, and cultural practices. Under TRIPs, this knowledge is largely unprotected.

Indigenous peoples and local communities often welcome interest in their knowledge as long as their rights as holders of this knowledge are respected – but they condemn its commercial exploitation by outside parties who feel no obligation to share benefits back with the communities that developed it. The term for this practice is biopiracy – defined broadly as the unauthorised appropriation of living organisms and the traditional cultural knowledge that accompanies them.

Several cases have illustrated this problem vividly. A US company, RiceTec, sought patents on Basmati rice varieties that had been cultivated in South Asia for centuries, prompting fierce objections from India and Pakistan. In another case, the US Patent Office initially granted a patent on properties of the Neem tree – long used in traditional Indian medicine and agriculture – before legal challenges forced a reversal. These cases show what can happen when Western-style patent systems, which prioritise formal documentation and individual ownership, encounter knowledge systems built on oral tradition and community stewardship.

The legal infrastructure required to file and defend intellectual property rights is often beyond the practical reach of indigenous communities, meaning that even where TRIPs theoretically allows for protection, the actual ability to benefit from that protection remains inaccessible. Critics argue that TRIPs’ IP standards were designed to establish corporate monopolies globally, but are structurally weak when it comes to protecting indigenous knowledge and preventing biopiracy.

Calls for reform: Article 27.3(b) and beyond 🔗

The Africa Group, along with nations across Latin America and India, have proposed reforms to Article 27.3(b) that would prohibit patents on life forms and ensure that any plant variety protection system can accommodate the rights of indigenous and local farming communities. These proposals have met resistance from the United States and the European Union, who have blocked meaningful reform at successive WTO meetings. The TRIPS Council continues to examine the relationship between the agreement and the Convention on Biological Diversity, as well as the protection of traditional knowledge and folklore – but formal resolution remains elusive.

The core tension: innovation incentives vs. public interest 🔗

The fundamental debate around TRIPs comes down to a single unresolved tension. Intellectual property protection incentivises innovation. Without the assurance that they can recoup investment through temporary monopoly rights, pharmaceutical companies, technology firms, and agricultural researchers would have weaker incentives to develop new products. TRIPs frames the IP system in terms of innovation, technology transfer, and public welfare – and its supporters argue that the agreement, however imperfect, provides a foundation for global knowledge-sharing.

But the critics – including Nobel laureate economist Joseph Stiglitz – argue that the agreement as designed does not achieve this balance. Stiglitz contended that TRIPs imposed the dominant intellectual property regime of the United States and Europe on the entire world, and that this regime was not in the interests of developing countries – and arguably not even in the long-term interest of the countries that championed it. TRIPs’ wealth concentration effects – moving money from people in developing countries to patent and copyright holders in developed countries – and its imposition of artificial scarcity on citizens who would otherwise have had access to weaker IP regimes, are among the most cited criticisms.

One structural difficulty facing developing countries is that even when TRIPs explicitly allows flexibility – for compulsory licensing, for public health exceptions, for transition periods – the practical capacity to use these tools is often absent. The lack of legal and technical expertise needed to draft legislation that implements TRIPs flexibilities has often led developing countries to directly copy developed-country IP legislation, or to rely on technical assistance that encourages stronger IP monopolies rather than more nuanced approaches. This means that even the spaces for manoeuvre that TRIPs formally provides may remain out of reach for the countries that need them most.

Where things stand: ongoing debates and partial reforms 🔗

The TRIPs story is not static. The 2001 Doha Declaration was a genuine, if partial, victory for developing countries. The 2017 amendment to TRIPs on pharmaceutical exports represents a structural change, even if its use has been limited. Following the Doha Declaration, several compulsory licences were issued for generic manufacture of patented drugs, with countries like Thailand developing explicit strategies of using compulsory licensing to reduce healthcare costs.

Meanwhile, discussions about the protection of traditional knowledge and the reform of agricultural patent provisions continue in the TRIPS Council. The Nagoya Protocol on access and benefit-sharing under the Convention on Biological Diversity has provided a complementary framework, though its interface with TRIPs remains unresolved. Some indigenous communities have begun developing their own solutions – community-based knowledge registers and collective IP frameworks – to assert control over their heritage outside the formal patent system.

What remains clear is that a global intellectual property regime designed primarily by and for technologically advanced, capital-rich economies will not automatically serve the interests of the world’s poorest communities. Finding a version of TRIPs that genuinely balances innovator protection with equitable access – and that recognises traditional knowledge as deserving protection, not appropriation – is still a work in progress.

What do you think? Should international IP rules like TRIPs be fundamentally redesigned to give developing countries more flexibility, or can the existing framework – with targeted reforms like the Doha Declaration – adequately address the imbalances it has created? And how should global trade law be changed to genuinely protect indigenous knowledge systems that predate the modern patent system by generations?

References

1. https://www.wto.org/english/tratop_e/trips_e/intel2_e.htm
2. https://en.wikipedia.org/wiki/TRIPS_Agreement
3. https://eur-lex.europa.eu/EN/legal-content/summary/wto-agreement-on-trade-related-aspects-of-intellectual-property.html
4. https://www.eff.org/issues/trips
5. https://www.uspto.gov/ip-policy/patent-policy/trade-related-aspects-ip-rights
6. https://globalizationandhealth.biomedcentral.com/articles/10.1186/1744-8603-1-17
7. https://msfaccess.org/spotlight-trips-trips-plus-and-doha
8. https://www.wto.org/english/tratop_e/trips_e/pharmpatent_e.htm
9. https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm
10. https://www.wto.org/english/tratop_e/trips_e/art27_3b_e.htm
11. https://ictsd.iisd.org/bridges-news/bridges/news/developing-countries-and-trips-a-case-for-a-full-fledged-review-of-article
12. https://www.iatp.org/sites/default/files/Indigenous_Peoples_Bioprospecting_and_the_TRIP.htm
13. https://ipmall.law.unh.edu/sites/default/files/hosted_resources/PLANT_PATENT_ARTICLES/biopiracy_and_indigenous_knowledges.pdf
14. https://pmc.ncbi.nlm.nih.gov/articles/PMC3483946/
15. https://www.iatp.org/sites/default/files/Promoting_Biopiracy_Blocking_TRIPs_Reform_Seat.htm
16. https://www.wto.org/trips
17. https://pmc.ncbi.nlm.nih.gov/articles/PMC3699798/